Cargando…

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth

Epidermal growth factor receptor (EGFR) activation plays a pivotal role in EGFR-driven non-small cell lung cancer (NSCLC) and is considered as a key target of molecular targeted therapy. EGFR tyrosine kinase inhibitors (TKIs) have been canonically used in NSCLC treatment. However, prevalent innate a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Nan, Wang, Chen-Ran, Liu, Ming-Qun, Li, Ying-Jie, Chen, Wei-Min, Li, Zheng-Qiu, Qi, Qi, Lu, Jin-Jian, Fan, Chun-Lin, Chen, Min-Feng, Qi, Ming, Li, Xiao-Bo, Hong, Jian, Zhang, Dong-Mei, Ye, Wen-Cai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544691/ https://www.ncbi.nlm.nih.gov/pubmed/33033232 http://dx.doi.org/10.1038/s41392-020-00251-2

Ejemplares similares

FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth
por: Niu, Mengmeng, et al.
Publicado: (2021)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
por: Li, Yang‐ling, et al.
Publicado: (2019)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Prognostic value of CYFRA 21 − 1 and Ki67 in advanced NSCLC patients with wild-type EGFR
por: Li, Tao, et al.
Publicado: (2023)

Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
por: Zhu, Yan-juan, et al.
Publicado: (2017)

Sulforaphane attenuates EGFR signaling in NSCLC cells
por: Chen, Chi-Yuan, et al.
Publicado: (2015)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR
por: Zhou, Yanhua, et al.
Publicado: (2022)

Unexpected responses to EGFR inhibition in NSCLC
por: Stella, Giulia M., et al.
Publicado: (2015)

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients
por: Su, Jian, et al.
Publicado: (2017)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC
por: Che, Ting-Fang, et al.
Publicado: (2015)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

N‐glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC
por: Han, Chia‐Li, et al.
Publicado: (2021)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway
por: Shao, Jingwei, et al.
Publicado: (2017)

Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection
por: Sung, Mike R., et al.
Publicado: (2021)

EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction
por: Kumarakulasinghe, Nesaretnam Barr, et al.
Publicado: (2016)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
por: Wu, Wen-Shuo, et al.
Publicado: (2014)

Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours
por: Yue-Yun, Chen, et al.
Publicado: (2019)

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
por: Sun, Li, et al.
Publicado: (2021)

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
por: Paz-Ares, Luis, et al.
Publicado: (2014)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
por: Karachaliou, Niki, et al.
Publicado: (2019)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC
por: Kobayashi, Keigo, et al.
Publicado: (2023)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
por: Sattler, Martin, et al.
Publicado: (2008)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations
por: Shi, Puyu, et al.
Publicado: (2019)

晚期EGFR阳性NSCLC患者PD-L1表达特点及其与EGFR-TKIs治疗疗效关系的真实世界研究
por: CHEN, Ran, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jsbe6ke0qof3s9imf5m0h4tmjq